Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
FDA feedback expected in Q4 2026 on proposed use of new formulation of brilaroxazine in the RECOVE
FDA feedback expected in Q4 2026 on proposed use of new formulation of brilaroxazine in the RECOVE